Price Indexes for Clinical Trial Research: A Feasibility Study
Price Indexes for Clinical Trial Research: A Feasibility Study
复制标题
临床试验研究的价格指数：可行性研究
DOI：
10.3386/w18918
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
I. Cockburn
中科院分区：
文献类型：
--
作者：
E. Berndt;I. Cockburn
我们使用从 Medidata Solutions Worldwide Inc. 获得的试验申办者和临床研究者之间的大量协议样本，估算了临床试验研究的特征价格指数，这是生物医学研发的重要组成部分。1989 年至 2011 年间，以每名患者的总资助成本衡量的名义价格上涨了 4.5 倍，而关注投入成本的 NIH 生物医学研发价格指数 (BRDPI) 仅上涨了 2.2 倍。大部分差异似乎归因于临床试验的性质和组织的变化：在此期间，每个中心的平均患者人数大幅下降，而“现场工作量”增加了一倍多。在使用基于特征回归的各种方法控制研究者协议特征的这些变化后，我们发现临床试验成本的估计通货膨胀率与 BDRPI 非常接近。这项研究的结果表明，统计机构为此类研发活动制定生产者价格指数应该是可行的，从而有助于为合同研发服务制定平减指数。
We estimate hedonic price indexes for clinical trial research, an important component of biomedical R&D, using a large sample of agreements between trial sponsors and clinical investigators obtained from Medidata Solutions Worldwide Inc. Nominal prices measured as total grant cost per patient rose by a factor of 4.5 between 1989 and 2011, while the NIH Biomedical R&D Price Index (BRDPI) focused on input costs rose only 2.2-fold. Most of the disparity appears to be attributable to changes in the nature and organization of clinical trials: during this period the average number of patients per site fell substantially while "site work effort" more than doubled. After controlling for these changes in the characteristics of investigator agreements using a variety of methods based on hedonic regressions, we find that the estimated rate of inflation in clinical trials costs tracks the BDRPI very closely. Results from this study suggest that it should be feasible for statistical agencies to develop a producer price index for this type of R&D activity, contributing to broader efforts to develop a deflator for contracted R&D services.